Extended Data Fig. 2: Characterization of pathological Tau in mouse model.
a. Schematic drawing of tau acceleration model, created in BioRender; Qian, C. https://BioRender.com/3hrufq2(2026). b. Left: representative images of staining of various phospho-Tau epitope on brain sections from PS19 mice treated with mutant Tau. Selected areas are shown magnified to the left of each image. Scale bar: 100 μm. Right: quantification analysis of the percent of each phospho-Tau epitope in AT8-positive cells. n = 10 mice. 13w: 13-week-old. c. Left: representative images of staining of various phospho-Tau epitope on brain sections from 9-month-old (9 M) PS19 mice. Selected areas are shown magnified to the left of each image. Scale bar: 50 μm. Right: quantification analysis of the percent of each phospho-Tau epitope in AT8-positive cells. n = 10 mice. d. Upper: representative images of X34 and AT8 staining on brain sections from PS19 mice treated with mutant Tau. Scale bar: 50 μm. Lower: quantification analysis of the percent of X34 in AT8-positive cells. n = 10 mice. e. Upper: representative images of X34 and AT8 staining on brain sections from 9-month-old PS19 mice. Scale bar: 50 μm. Lower: Quantification analysis of the percent of X34 in AT8-positive cells. n = 10 mice. f. Upper: representative images of pMLKL and NeuN staining on brain sections from PS19 mice treated with mutant Tau. Scale bar: 10 μm. Lower: quantification analysis of the percent of pMLKL-positive neurons. n = 10 mice. g. Left: representative images of IBA1 and GFAP staining on brain sections from PS19 mice treated with mutant Tau. Scale bar: 300 μm. Selected areas are shown at higher magnification. Right: quantification of relative intensity of IBA1 and GFAP. Sham PS19: n = 8 mice, Tau injected PS19: n = 10 mice. Significance between two groups is determined by two-tailed unpaired t-test (f, g). Data are mean ± s.e.m.
